Latest NewsFDA NewsAdverse Event ManagementSupportive CareDisparities in Cancer CareDrug SafetyRadiation OncologySurvivorship Practice ManagementPreventionContributorsSponsored
Expert ConnectionsMorning RoundsThe VitalsPodcastsVideosBetween the LinesFrom All AnglesMeeting of the MindsTraining Academy
Conference CoverageConference Listing
Publications
Continuing Education
Case-Based Digest Rx Road MapWebinarsCancer Summary SlidesMPN Symptom ManagementEvents
SubscribePartners
Brain Cancer
Breast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head and Neck Cancers
HematologyHematologyHematologyHematologyHematologyHematology
Lung Cancer
Pediatric Cancer
Sarcomas
Skin CancerSkin Cancer
Advanced Practice Corner Logo
    Brain Cancer
    Breast CancerBreast Cancer
    Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
    Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
    Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
    Head and Neck Cancers
    HematologyHematologyHematologyHematologyHematologyHematology
    Lung Cancer
    Pediatric Cancer
    Sarcomas
    Skin CancerSkin Cancer
    Advanced Practice Corner Logo
        • Publications
        • Subscribe
        • Partners
      Advertisement

      Providers Must Give Reliable Information on Immune-Related AEs

      August 28, 2019
      By Brielle Benyon
      Article

      Patients are getting a ton of information from outside sources and advertisements about new immunotherapy agents. It is crucial that providers offer them the key facts that they need.

      Providers must clearly outline potential immune-related adverse events for their patients with lung cancer, and in managing these toxicities, it is crucial that a team approach is used to ensure the best possible care, explained Benjamin Levy, MD.

      “We have to be communicative with our patients and let them lead the way in informing us when they're having some of these side effects,” Levy, associate professor at Johns Hopkins School of Medicine and clinical director of the Johns Hopkins Sidney Kimmel Cancer Center in Washington DC. said in a recent interview with Oncology Nursing News®.

      Oncology Nursing News®: Can you give an overview of managing adverse events from immunotherapy?

      Levy: Immunotherapy obviously has altered the treatment paradigm for patients. It's been transformative. We're seeing long-term outcomes, 5-year survival rates that we've never seen before the treatment of immunotherapy.

      We need to be cognizant, however, that these drugs do have side effects, specifically immune-related side effects. We need to educate our patients about them; we need to educate other providers who are participating in the care of patients, and we need to be collaborative. These immune-related adverse events include everything from pneumonitis to colitis, to hepatitis, to abnormalities in thyroid functioning, as well as rash.

      We have to be mindful when we're starting these patients to make sure that they're aware of them and to call us when they're experiencing some of these side effects. Again, we need to communicate with other providers on the team so that we can make sure that we treat these patients appropriately and proactively.

      How do you recommend patients go about talking about this with their providers?

      Importantly, the dialogue has to start with the providers. These patients are receiving a lot of information about these drugs, either through magazines or through direct-to-consumer advertising, and they don't understand that these drugs do have side effects. I tell patients, 'you have to be proactive. If you develop an acute fever and cough, that may be an indication that you have a rare immune-related adverse event called pneumonitis, and we need to be proactive and treat that right away.'

      Do adverse events impact a practitioner's decision to give a patient immunotherapy or not?

      What we've learned from immunotherapy in combination with chemotherapy, which is now the standard of care for all patients without actionable mutations who are immunotherapy eligible, advanced adenocarcinoma and advanced squamous cell carcinoma, is that the rate that we're seeing for immune-related adverse events is no higher than we see with single-agent immunotherapy. So there are a lot of questions. If I add immunotherapy to chemotherapy, won't that increase the chance that the patient develops and immune-related adverse event? That's not what we're seeing in KEYNOTE-189, that's not what we're seeing in KEYNOTE-487, that's not what we're seeing in KEYNOTE-407, it's not what we're seeing in IMpower4150. Yes, there are immune-related adverse events there in combination approaches, but they're no higher than expected with single-agent immunotherapy.

      The onus is still on the [providers] to educate the patients about these side effects. But it's not that we're using them in combination with chemotherapy and seeing them more frequently. I think they're there, and again, we need to be mindful of them and patients need to be mindful of them, and we need to have a low threshold to refer our patients to sub-specialists like gastroenterologists, pulmonologists, and endocrinologists, but I think that we've been reassured that these are manageable toxicities, even when you combine them with chemotherapy.

      Read more: Five Pillars Nurses Should Follow in Treating Immune-Related Adverse Events

      Newsletter

      Stay up to date on recent advances in oncology nursing and patient care.

      Subscribe Now!
      Recent Videos
      Image of multiple myeloma cells
      4 experts in this video
      4 experts in this video
      Related Content

      White lungs against a blue background

      NCCN Adds Zongertinib to HER2+ Non–Small Cell Lung Cancer Guidelines

      Bridget Hoyt
      August 22nd 2025
      Article

      The Vitals

      Nicole Gay Shares How She Counsels Patients on Lung Cancer Screenings

      Lindsay Fischer
      August 22nd 2025
      Podcast

      graphic of a seal that reads "FDA approved"

      Zongertinib Nabs FDA Approval in Nonsquamous HER2 TKD+ NSCLC

      Bridget Hoyt
      August 22nd 2025
      Article

      Oncology Nursing News

      A Look Back at 2022 FDA Approvals in Oncology

      Oncology Nursing News
      August 22nd 2025
      Podcast

      Graphic of a seal that reads "FDA Approved"

      July FDA Oncology Approvals Include Options for NSCLC, Myeloma, and More

      Bridget Hoyt
      August 22nd 2025
      Article

      Line illustration of lungs

      Opinion: Comprehensive Genomic Profiling Is Vital for Optimizing NSCLC Care

      Amanda Brink, DNP, APRN, FNP-BC, AOCNP
      August 22nd 2025
      Article
      Related Content

      White lungs against a blue background

      NCCN Adds Zongertinib to HER2+ Non–Small Cell Lung Cancer Guidelines

      Bridget Hoyt
      August 22nd 2025
      Article

      The Vitals

      Nicole Gay Shares How She Counsels Patients on Lung Cancer Screenings

      Lindsay Fischer
      August 22nd 2025
      Podcast

      graphic of a seal that reads "FDA approved"

      Zongertinib Nabs FDA Approval in Nonsquamous HER2 TKD+ NSCLC

      Bridget Hoyt
      August 22nd 2025
      Article

      Oncology Nursing News

      A Look Back at 2022 FDA Approvals in Oncology

      Oncology Nursing News
      August 22nd 2025
      Podcast

      Graphic of a seal that reads "FDA Approved"

      July FDA Oncology Approvals Include Options for NSCLC, Myeloma, and More

      Bridget Hoyt
      August 22nd 2025
      Article

      Line illustration of lungs

      Opinion: Comprehensive Genomic Profiling Is Vital for Optimizing NSCLC Care

      Amanda Brink, DNP, APRN, FNP-BC, AOCNP
      August 22nd 2025
      Article

      Latest Conference Coverage

      How Nurses Can Assess and Manage Talquetamab Toxicities

      Transformative Care: A Nurse Guide to Novel Therapies in Blood Cancers

      Personalized Cancer Vaccines: Watching For Immune-Related, Vaccine AEs

      Nurses, APPs Key to AE Management as T-Cell Engagers Move Into Solid Tumors

      View More Latest Conference Coverage
      About Us
      Editorial Board
      Contact Us
      CancerNetwork.com
      CureToday.com
      OncLive.com
      TargetedOnc.com
      Advertise
      Privacy
      Terms & Conditions
      Do Not Sell My Information
      Contact Info

      2 Commerce Drive
      Cranbury, NJ 08512

      609-716-7777

      © 2025 MJH Life Sciences

      All rights reserved.